Received Oct 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Fatigue; Muscle ache; Headache; This non-serious case was reported by a consumer via call center representative and described the occurrence of fatigue in a male patient who received Herpes zoster (Shingrix) for prophylaxis. On 07-OCT-2025, the patient received Shingrix. In OCT-2025, less than a week after receiving Shingrix, the patient experienced fatigue (Verbatim: Fatigue), muscle pain (Verbatim: Muscle ache) and headache (Verbatim: Headache). The outcome of the fatigue, muscle pain and headache were unknown. It was unknown if the reporter considered the fatigue, muscle pain and headache to be related to Shingrix and Shingrix Pre-Filled Syringe Device. It was unknown if the company considered the fatigue, muscle pain and headache to be related to Shingrix and Shingrix Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 08-OCT-2025 The reporter stated that he had Shingrix administered 07th October 2025. The healthcare professional stated that he had muscle aches, fatigue and headache. Consumer declined to provide any information or demographic information.